Encouragement to pharmaceutical companies to register medicines commonly used in Named Patient Programmes

List of the most commonly used NPP medicines in April.

15.5.2020

The Icelandic Medicines Agency (IMA) hereby publishes a list of the most commonly prescribed medicinal products in Named Patient Programmes (NPPs) in April 2020. The list only includes approved prescriptions.

The purpose of publishing this information is to encourage pharmaceutical companies to apply for marketing authorisations and market the products listed, or comparable medicines. The advantage of having a medicinal product authorised and marketed, is that NPP prescriptions are usually not approved by IMA if a comparable medicinal product with an MA is marketed. It is therefore beneficial for all parties involved to have proper registration for the medicinal products that are sold in Iceland. Benefits for users include updated information in Icelandic, for both healthcare professionals and patients.

Most of the medicinal products listed below are absent from the market, whereas a few of them (starred) are temporary substitutions for registered medicinal products.

This list only includes medicinal products used in NPPs prescribed to individuals, but neither includes unregistered medicines used at hospitals and health institutions, nor medicines prescribed by veterinarians.

*	Medicinal product	ATC code	Number of approved prescriptions in April
	Doloproct suppositories	C05AA08	655
	Xyloproct suppositories	C05AA01	339
	Senokot	A06AB06	161
*	Nifurantin	J01XE01	139
	Bromam	N05BA08	117
*	Uro-Tablinen	J01XE01	114
	Co-Trimoxazole	J01EE01	102
*	Nozinan	N05AA02	99
*	Levomepromazine Orion	N05AA02	97
*	Naprosyn entero	M01AE02	84
*	Duac once daily	D10AF51	77
	SEM mixture	R05DA20	74
	Quinine Sulfate	P01BC01	68
	Rohypnol	N05CD03	65
	Miralax	A06AD	46
	Methopromazine	N05AA02	43
	Phenhydan	N03AB02	39
	Glycerol Infant	A06AX01	36
	Largactil	N05AA01	35
*	Naproxen	M01AE02	35